Table 3.

Multivariable Logistic and Tobit Regression Analyses for the Presence and Extent of CAC.

	CAC Presence		CAC Extent
	OR (95% CI)	p-Value	β (SE)	p-Value
Model 1: FRS, Site, Race, Menopausal status, Income, Education
hsCRP, mg/L	1.86 (1.52–2.31)	<0.0001	16.232 (4.155)	<0.0001
Fibrinogen, mg/dL	7.07 (2.01–24.94)	0.002	74.200 (25.917)	0.004
PAI-1, ng/mL	1.72 (1.32–2.25)	<0.0001	19.683 (5.240)	0.0002
tPA-ag, ng/mL	3.74 (2.08–6.74)	<0.0001	31.910 (9.330)	0.0006
Factor VIIc, %	4.14 (1.41–12.11)	0.01	53.611 (19.689)	0.007
Model 2: Model 1 + BMI
hsCRP, mg/L	1.19 (0.92–1.54)	0.2	7.107 (4.580)	0.1
Fibrinogen, mg/dL	1.60 (0.34–7.52)	0.6	49.139 (26.803)	0.07
PAI-1, ng/mL	1.04 (0.75–1.44)	0.8	10.719 (5.644)	0.06
tPA-ag, ng/mL	1.36 (0.70–2.61)	0.4	15.933 (9.942)	0.1
Factor VIIc, %	2.57 (0.77–8.61)	0.1	47.284 (19.930)	0.02
Model 3: Model 2 + Log(HOMA), Family history, CV medication use
hsCRP, mg/L	1.16 (0.88–1.53)	0.3	5.769 (4.958)	0.2
Fibrinogen, mg/dL	2.22 (0.40–12.28)	0.4	51.812 (28.639)	0.07
PAI-1, ng/mL	0.83 (0.57–1.22)	0.3	7.474 (6.514)	0.3
tPA-ag, ng/mL	0.88 (0.43–1.79)	0.7	7.754 (10.917)	0.5
Factor VIIc, %	2.78 (0.72–10.71)	0.1	46.721 (21.183)	0.03

All inflammatory/hemostatic biomarkers were log transformed.

BMI = body mass index; CAC = coronary artery calcification; CV = cardiovascular; FRS = Framingham risk score; hsCRP = high sensitivity C-reactive proteins; OR = odds ratio; PAI-1 = plasminogen-activator inhibitor 1; tPA-ag = tissue plasminogen activator antigen